{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The event-free survival distributions of patients with Stage I focal and diffuse anaplastic Wilms tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":".0570","paramType":"Log Rank Test Statistic","paramValue":"3.6216","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100.0","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610).","dispersionType":"95% Confidence Interval","groups":[{"description":"Vincristine/dactinomycin/doxorubicin x25 weeks; XRT.","id":"OG000","title":"Regimen DD-4A"}],"paramType":"NUMBER","populationDescription":"Eligible patients with Stage I focal and diffuse anaplastic Wilms tumor.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Event Free Survival Probability","type":"PRIMARY","unitOfMeasure":"Percent Probability 4 Year EFS"}